Pfizer (NYSE:PFE) Stock Price Down 2.1% – Here’s Why

Pfizer Inc. (NYSE:PFE) shares were down 2.1% on Monday . The stock traded as low as $25.48 and last traded at $25.6180. Approximately 34,959,832 shares traded hands during mid-day trading, a decline of 16% from the average daily volume of 41,525,152 shares. The stock had previously closed at $26.18.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced a global oncology partnership with Innovent Biologics worth up to $10.5 billion, expanding its pipeline with 12 early-stage cancer programs and reinforcing its push into next-generation cancer therapies.
• Positive Sentiment: New Phase 3 BREAKWATER data showed Pfizer’s BRAFTOVI regimen nearly doubled median progression-free survival in previously untreated BRAF V600E metastatic colorectal cancer, strengthening the commercial outlook for the drug.
• Positive Sentiment: Seven-year follow-up from the Phase 3 CROWN trial showed sustained protection from LORBRENA against disease progression and brain metastases in ALK-positive advanced lung cancer, supporting the durability of Pfizer’s oncology franchise.
• Neutral Sentiment: Pfizer also announced that CEO Albert Bourla will speak at the Goldman Sachs Global Healthcare Conference on June 8, which could provide investors with updates on strategy but is not a direct business catalyst.
• Neutral Sentiment: Additional articles discussed Pfizer as a potential value stock and as a possible defensive holding if markets become volatile, but these pieces were opinion-based rather than company-specific news.
• Negative Sentiment: Longer-term commentary noted that Pfizer has underperformed many healthcare peers and remains well below prior highs, keeping some investors cautious despite the recent pipeline progress.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on PFE shares. Cantor Fitzgerald restated a “neutral” rating on shares of Pfizer in a research report on Monday. Barclays started coverage on shares of Pfizer in a research report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price target on the stock. Citigroup boosted their price target on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. Guggenheim boosted their price target on shares of Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Finally, Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, eleven have issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $28.82.

Pfizer Price Performance

The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The firm’s 50 day simple moving average is $26.77 and its 200 day simple moving average is $26.29. The company has a market capitalization of $146.01 billion, a PE ratio of 19.56 and a beta of 0.34.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. Pfizer’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, research analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s payout ratio is currently 131.30%.

Institutional Trading of Pfizer

A number of large investors have recently made changes to their positions in the stock. Concorde Asset Management LLC purchased a new stake in shares of Pfizer during the first quarter valued at $237,000. Financial Solutions Advisory Group Inc. purchased a new stake in shares of Pfizer during the first quarter valued at $770,000. Integrated Investment Consultants LLC boosted its stake in shares of Pfizer by 8.5% during the first quarter. Integrated Investment Consultants LLC now owns 55,332 shares of the biopharmaceutical company’s stock valued at $1,554,000 after purchasing an additional 4,320 shares during the period. Lavelle Capital LP purchased a new stake in Pfizer in the first quarter worth about $842,000. Finally, Allen Capital Group LLC lifted its stake in Pfizer by 7.8% in the first quarter. Allen Capital Group LLC now owns 211,583 shares of the biopharmaceutical company’s stock worth $5,941,000 after acquiring an additional 15,347 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.